Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved..
SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis presents findings from over 6,500 outpatient administrations of mAb at facilities affiliated with a large healthcare organization in the United States. Within 48 hours of mAb infusion, 15.6% (1,043) of patients received a drug that was indicative of a possible reaction to the infusion; the majority of these were mild (e.g., acetaminophen). Approximately 5.2% of patients who received mAb (n=347) had a post-infusion emergency department visit or admission for COVID-19 disease progression. The results of this analysis indicate that patients who receive mAb have a low likelihood of both an immediate negative reaction to the treatment as well as future inpatient admission related to COVID-19 disease progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 112(2021) vom: 01. Nov., Seite 73-75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goldin, Laurel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2021.09.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330510703 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330510703 | ||
| 003 | DE-627 | ||
| 005 | 20231225211435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.09.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330510703 | ||
| 035 | |a (NLM)34508863 | ||
| 035 | |a (PII)S1201-9712(21)00713-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goldin, Laurel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis presents findings from over 6,500 outpatient administrations of mAb at facilities affiliated with a large healthcare organization in the United States. Within 48 hours of mAb infusion, 15.6% (1,043) of patients received a drug that was indicative of a possible reaction to the infusion; the majority of these were mild (e.g., acetaminophen). Approximately 5.2% of patients who received mAb (n=347) had a post-infusion emergency department visit or admission for COVID-19 disease progression. The results of this analysis indicate that patients who receive mAb have a low likelihood of both an immediate negative reaction to the treatment as well as future inpatient admission related to COVID-19 disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Sars-Co-V-2 | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Elders, Ty |e verfasserin |4 aut | |
| 700 | 1 | |a Werhane, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Korwek, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Poland, Russell |e verfasserin |4 aut | |
| 700 | 1 | |a Guy, Jeffrey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 112(2021) vom: 01. Nov., Seite 73-75 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2021 |g day:01 |g month:11 |g pages:73-75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2021.09.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2021 |b 01 |c 11 |h 73-75 | ||